Defining the Role of Renal Transplantation in the Modern Management of Multiple Myeloma and Other Plasma Cell Dyscrasias

Nephron ◽  
2012 ◽  
Vol 120 (4) ◽  
pp. c228-c235 ◽  
Author(s):  
Tarun Bansal ◽  
Anshu Garg ◽  
John A. Snowden ◽  
William McKane
Keyword(s):  
Multiple Myeloma ◽  
Renal Transplantation ◽  
Plasma Cell ◽  
Modern Management ◽  
Plasma Cell Dyscrasias

scholarly journals NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias

Cells ◽  
2020 ◽  
Vol 9 (3) ◽  
pp. 768 ◽  
Author(s):  
Renato Zambello ◽  
Gregorio Barilà ◽  
Sabrina Manni ◽  
Francesco Piazza ◽  
Gianpietro Semenzato
Keyword(s):  
Multiple Myeloma ◽  
Monoclonal Antibodies ◽  
Immune System ◽  
Nk Cells ◽  
Plasma Cell ◽  
Potential Role ◽  
Myeloma Cell ◽  
Initial Reduction ◽  
Plasma Cell Dyscrasias

Immunotherapy represents a promising new avenue for the treatment of multiple myeloma (MM) patients, particularly with the availability of Monoclonal Antibodies (mAbs) as anti-CD38 Daratumumab and Isatuximab and anti-SLAM-F7 Elotuzumab. Although a clear NK activation has been demonstrated for Elotuzumab, the effect of anti-CD38 mAbs on NK system is controversial. As a matter of fact, an initial reduction of NK cells number characterizes Daratumumab therapy, limiting the potential role of this subset on myeloma immunotherapy. In this paper we discuss the role of NK cells along with anti-CD38 therapy and their implication in plasma cell dyscrasias, showing that mechanisms triggered by anti-CD38 mAbs ultimately lead to the activation of the immune system against myeloma cell growth.

scholarly journals The Role of the Gut Microbiome in Pathogenesis, Biology, and Treatment of Plasma Cell Dyscrasias

2021 ◽  
Vol 11 ◽  
Author(s):  
Marcin Jasiński ◽  
Jarosław Biliński ◽  
Grzegorz W. Basak
Keyword(s):  
Multiple Myeloma ◽  
Gut Microbiota ◽  
Plasma Cell ◽  
Response To Treatment ◽  
Faecal Microbiota ◽  
Myeloma Cells ◽  
Risk Of Progression ◽  
Plasma Cell Dyscrasias ◽  
Refractory Malignancy

In response to emerging discoveries, questions are mounting as to what factors are responsible for the progression of plasma cell dyscrasias and what determines responsiveness to treatment in individual patients. Recent findings have shown close interaction between the gut microbiota and multiple myeloma cells. For instance, that malignant cells shape the composition of the gut microbiota. We discuss the role of the gut microbiota in (i) the development and progression of plasma cell dyscrasias, and (ii) the response to treatment of multiple myeloma and highlight faecal microbiota transplantation as a procedure that could modify the risk of progression or sensitize refractory malignancy to immunotherapy.

Anemia in Multiple Myeloma: Role of Deregulated Plasma Cell Apoptosis

2002 ◽  
Vol 43 (8) ◽  
pp. 1527-1533 ◽  
Author(s):  
Marco Tucci ◽  
Daniela Grinello ◽  
Paola Cafforio ◽  
Franco Silvestris ◽  
Franco Dammacco
Keyword(s):  
Multiple Myeloma ◽  
Plasma Cell ◽  
Cell Apoptosis

The role of CD81 for plasma cell dyscrasias

2014 ◽  
Vol 38 (3) ◽  
pp. 292-293 ◽  
Author(s):  
Mascha Binder ◽  
Ulrike Bacher
Keyword(s):  
Plasma Cell ◽  
Plasma Cell Dyscrasias

Multiple Myeloma and Plasma Cell Dyscrasias

2010 ◽  
pp. 640-666
Author(s):  
Noopur Raje ◽  
Kenneth C. Anderson ◽  
David M. Dorfman ◽  
Arthur T. Skarin
Keyword(s):  
Multiple Myeloma ◽  
Plasma Cell ◽  
Plasma Cell Dyscrasias

Multiple Myeloma and Related Plasma Cell Dyscrasias

JAMA ◽  
1987 ◽  
Vol 258 (20) ◽  
pp. 2930 ◽  
Author(s):  
Elliott F. Osserman
Keyword(s):  
Multiple Myeloma ◽  
Plasma Cell ◽  
Plasma Cell Dyscrasias
Sign in / Sign up

Export Citation Format

Share Document